ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Related Articles

Yanet Isabel Carrasco Rojas, Albert Gabriel Turpo Peqqueña, Natalia Camila Zenteno Tejada, Victoria Elena Quispe Pastor, Juan Augusto Martínez San Martín, Evelyn Maria Chambilla Huellcacure
Jeanine Justiniano, Ally H Mwanga, Daniel W Kitua, Nashivai E Kivuyo, Seif Wibonela, Cameron E Gaskill
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston
Jessica J Farzan, Jiddu Guart, Gabriel De la Cruz Ku, Nichita Kulkarni, Rachel Huselid, Anshumi Desai, Camila Franco, Vanessa Mroueh, Jessica Mroueh, Gonzalo Ziegler
Agodirin Olayide, Chijioke Chijindu, Mustapha Fathi, Rahman Ganiyu, Olatoke Samuel, Olaogun Julius, Akande Halima